146 related articles for article (PubMed ID: 8722423)
41. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
42. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
43. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
44. Session on the biology and treatment of neuroblastoma as related to metaiodobenzylguanidine. Chairmen's report.
Sisson JC; De Bernardi B
J Nucl Biol Med (1991); 1991; 35(4):199-201. PubMed ID: 1823818
[No Abstract] [Full Text] [Related]
45. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
46. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
[TBL] [Abstract][Full Text] [Related]
47. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
Peterson JA; Blank EW; Ceriani RL
Cancer Res; 1997 Mar; 57(6):1103-8. PubMed ID: 9067279
[TBL] [Abstract][Full Text] [Related]
48. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy.
Voûte PA; Hoefnagel CA; de Kraker J; Valdes Olmos R; Bakker DJ; van de Kleij AJ
Prog Clin Biol Res; 1991; 366():439-45. PubMed ID: 2068157
[No Abstract] [Full Text] [Related]
49. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
50. Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice.
Inui A; Chung YS; Sawada T; Kondo Y; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1996 Sep; 87(9):977-84. PubMed ID: 8878462
[TBL] [Abstract][Full Text] [Related]
51. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
52. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
53. High dose radioimmunotherapy in malignant lymphoma.
Eary JF; Press OW
Recent Results Cancer Res; 1996; 141():177-82. PubMed ID: 8722427
[No Abstract] [Full Text] [Related]
54. Opioid peptides as possible cause of pain reduction in neuroblastoma after admission of 131I-meta-iodobenzylguanidine.
Klingebiel T; Bruchelt G; Kaleva N; Wollmann H; Handgretinger R; Treuner J; Gupta D; Niethammer D
Prog Clin Biol Res; 1991; 366():509-12. PubMed ID: 2068167
[No Abstract] [Full Text] [Related]
55. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
[TBL] [Abstract][Full Text] [Related]
56. A human neuroblastoma xenograft model for 125-I-metaiodobenzylguanidine biodistribution studies.
Lavitrano M; Servidei T; Mastrangelo S; Tornesello A; Fioretti D; Di Stefano C; Riccardi A; Franceschini R; Riccardi R
J Neurooncol; 1997 Jan; 31(1-2):159-64. PubMed ID: 9049844
[TBL] [Abstract][Full Text] [Related]
57. The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.
Mairs RJ; Angerson W; Gaze MN; Murray T; Babich JW; Reid R; McSharry C
Br J Cancer; 1991 Mar; 63(3):404-9. PubMed ID: 2003981
[TBL] [Abstract][Full Text] [Related]
58. Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine-131 metaiodobenzylguanidine (MIBG).
Brendel AJ; Jeandot R; Guyot M; Lambert B; Drouillard J
Clin Nucl Med; 1989 Jan; 14(1):19-21. PubMed ID: 2714036
[No Abstract] [Full Text] [Related]
59. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
60. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
